Abstract:The duration of protection of hepatitis B vaccine remains incompletely understood. To assess the long-term protection provided by a primary vaccine series, the current study again recruited all subjects of a previous randomized placebo-controlled trial cohort 23 years after vaccination. Two hundred and sixty-one healthy children aged 5–9 years living in a highly HBV-endemic country were enrolled in the primary trial and received three doses of plasma-derived vaccine or placebo. The primary placebo receivers who did not receive any immunization against hepatitis B were used as non-vaccinated controls in the current study. After eliminating the interference of an early booster dose and vaccines outside the study, 48.1% (39/81) vaccinees still maintained anti-HBs titers ≥10mIU/mL at Year 23, higher than 34.7% (26/75) in non-vaccinated controls (P=0.088). 75–100% of vaccinees with anti-HBs titer <10mIU/mL at Year 23 in different sub-groups divided according to early immune backgrounds developed a rapid and robust antibody anamnestic response after a booster dose, highly significantly different from non-vaccinated controls who received the same dose of vaccine (7.5%, P<0.01). No case of clinically significant HBV infection was found in the primary cohort during the whole 23 years, but 10 transient HBsAg seroconversions in the primary placebo group and one in the primary vaccine group were determined. Anti-HBc positive rate obviously tended to be lower in vaccinees compared with non-vaccinated controls at Year 23. These results suggest a persisting immune memory and certain protection for 23 years after primary vaccination in children living in highly HBV-endemic areas. Clinically insignificant infections, which cannot be avoided and may often occur in vaccinees, play a positive role in the maintaining of immunity to HBV. Booster doses should be unnecessary for more than 20 years after a full primary immunization in children (as catch-up vaccination) and, also likely, in newborns living in highly HBV-endemic areas.

Requirement for Further Validation on the Seroconversion of Hepatitis B Surface Antigen in Successful Vaccinees.

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

Longitudinal Mapping of Hepatitis B Vaccine-Induced B-cell Linear Epitopes in Healthy Individuals

Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.

The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

Reply Letter Regarding Seroconversion of Hepatitis B Surface Antigen in a Successful Long-Term Immune Cohort

A serological and molecular survey of hepatitis B in children 15 years after inception of the national hepatitis B vaccination program in eastern China.

Antibody Levels and Immune Memory 23 Years after Primary Plasma-Derived Hepatitis B Vaccination: Results of a Randomized Placebo-Controlled Trial Cohort from China Where Endemicity is High

The One Year Effects of Three Doses of Hepatitis B Vaccine As a Booster in Anti-Hbs-negative Children 11–15 Years after Primary Immunization; China, 2009–2011

Be cautious for exceptional results in evaluating the effect of adolescent booster of hepatitis B vaccine.

Strategies for Hepatitis B Booster Vaccination among Children: an 8-Year Prospective Cohort Study

Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China

Protection and Antibody Levels 35 Years after Primary Series with Hepatitis B Vaccine and Response to a Booster Dose

The Response of Hepatitis B Vaccination on Seronegative Adults with Different Vaccination Schedules.

Long-term Persistence of Anti-Hbs after Hepatitis B Vaccination among Isolated Anti-Hbc Positive Adults in China: 8-Years Results

Hepatitis B Virus Vaccination in HIV: Immunogenicity and Persistence of Seroprotection up to 7 Years Following a Primary Immunization Course

The antibody persistence after immunisation with hepatitis B vaccine combined with different doses of hepatitis B immunoglobulin among infants born by HBsAg positive mothers: a three-year following-up study

Effects of hepatitis B vaccine boosters in different levels of epidemic areas on anti-HBs-negative children after primary vaccination

Comparison of Long-Term Immunogenicity (23 Y) of 10 Μg and 20 Μg Doses of Hepatitis B Vaccine in Healthy Children

Long-Term T-Cell-Mediated Immunologic Memory to Hepatitis B Vaccine in Young Adults Following Neonatal Vaccination.

Hepatitis B Revaccination in Healthy Non-Responder Chinese Children: Five-Year Follow-Up of Immune Response and Immunologic Memory.